Florez Laboratory at Dana-Farber launches International Pregnancy and Lung Cancer Registry

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Diaceutics has released research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer in the U.S. are still not receiving the most appropriate treatment.

May 01, 2026

Vol.52 No.17

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

Sen. Susan Collins and patient advocate Jill Feldman are recognized with AACR Distinguished Service Awards

The American Association for Cancer Research will honor leaders from government and the advocacy community with awards for distinguished service in support of cancer research at the AACR Annual Meeting 2026 to be held April 17-22 in San Diego.

April 17, 2026

Vol.52 No.15

Clinical Roundup

E-cigarette taxes reduce vaping; no increase in adult smoking, OSU study finds

For years, a central debate in tobacco policy has been whether taxing e-cigarettes might unintentionally drive vapers back to traditional cigarettes.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Lung cancer surgery safe for many patients over 80, Mount Sinai study finds

Adults aged 80 and older with early-stage lung cancer can safely undergo surgery and achieve outcomes comparable to younger patients, challenging longstanding assumptions about age and cancer treatment, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center.

April 10, 2026

Vol.52 No.14

Clinical Roundup

Researchers at VCU identify Achilles’ heel in lung cancer through common genetic mutation

A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA replication in cancer cells.

March 13, 2026

Vol.52 No.10

Florez Laboratory at Dana-Farber launches International Pregnancy and Lung Cancer Registry

YOU MAY BE INTERESTED IN

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Sen. Susan Collins and patient advocate Jill Feldman are recognized with AACR Distinguished Service Awards

E-cigarette taxes reduce vaping; no increase in adult smoking, OSU study finds

Lung cancer surgery safe for many patients over 80, Mount Sinai study finds

Researchers at VCU identify Achilles’ heel in lung cancer through common genetic mutation

Renew today!

Subscriber content

Never miss an issue!

Login

Florez Laboratory at Dana-Farber launches International Pregnancy and Lung Cancer Registry

YOU MAY BE INTERESTED IN

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Sen. Susan Collins and patient advocate Jill Feldman are recognized with AACR Distinguished Service Awards

E-cigarette taxes reduce vaping; no increase in adult smoking, OSU study finds

Lung cancer surgery safe for many patients over 80, Mount Sinai study finds

Researchers at VCU identify Achilles’ heel in lung cancer through common genetic mutation

Never miss an issue!

Login

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”